ARCHIMED has acquired Magellan Biologics & Consulting for an undisclosed amount, marking a significant corporate transaction in the life sciences sector. Magellan Biologics & Consulting, founded in 2014 as a spin-off of ExcellGene SA, specializes in Transient Protein Expression in mammalian cells. Its acclaimed CHO4Tx kits are widely utilized globally, providing a fast and efficient solution for producing small quantities of proteins and antibodies essential for research and development candidate screening programs.
Beyond its product offerings, Magellan Biologics & Consulting delivers a comprehensive suite of products, materials, and services designed to accelerate research and development within the pharma-biotech industry. The company supports a diverse client base, spanning both industrial and academic institutions, by streamlining fundamental steps in pre-clinical research and development. Magellan is also recognized for its unique and widely-acknowledged expertise, offering personalized advice and consultancy services.
This acquisition is strategically significant for ARCHIMED, enabling it to expand its presence and capabilities within the crucial pre-clinical R&D market. By integrating Magellan's specialized transient protein expression technology and deep expertise, ARCHIMED aims to enhance its portfolio of solutions supporting pharmaceutical and biotechnological innovation. The synergy between the two entities is expected to broaden the reach of Magellan’s established products and services, making critical research tools more accessible to a wider global audience.
The transaction underscores a commitment to advancing the tools and services vital for accelerating drug discovery and development. The combined entity is positioned to build upon Magellan's foundation of innovation and customer support, further enabling clients in both industry and academia to conduct their pre-clinical research more effectively and efficiently. This move reflects a continued investment in foundational scientific capabilities within the life sciences ecosystem.